Digital PCR Assays for Precise Quantification of CD19-CAR-T Cells after Treatment with Axicabtagene Ciloleucel.
Axi-cel
Axicabtagene Ciloleucel
CAR monitoring
Chimeric antigen receptor (CAR)
Yescarta
digital PCR (dPCR)
Journal
Molecular therapy. Methods & clinical development
ISSN: 2329-0501
Titre abrégé: Mol Ther Methods Clin Dev
Pays: United States
ID NLM: 101624857
Informations de publication
Date de publication:
13 Mar 2020
13 Mar 2020
Historique:
received:
21
12
2019
accepted:
24
12
2019
entrez:
15
2
2020
pubmed:
15
2
2020
medline:
15
2
2020
Statut:
epublish
Résumé
Treatment with axicabtagene ciloleucel (Axi-cel) CD19-CAR-T (chimeric antigen receptor T) cells has been approved for refractory/relapsed diffuse large B cell lymphoma (DLBCL) and primary mediastinal large B cell lymphoma (PMBCL). Because treatment success as well as side effects might depend on CAR-T cell expansion
Identifiants
pubmed: 32055645
doi: 10.1016/j.omtm.2019.12.018
pii: S2329-0501(20)30009-7
pmc: PMC7005515
doi:
Types de publication
Journal Article
Langues
eng
Pagination
172-178Informations de copyright
© 2020 The Author(s).
Références
J Immunother. 2009 Sep;32(7):689-702
pubmed: 19561539
N Engl J Med. 2018 Jul 5;379(1):64-73
pubmed: 29972754
Nat Protoc. 2016 Mar;11(3):598-615
pubmed: 26914317
Biotechniques. 1992 Sep;13(3):444-9
pubmed: 1389177
Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638
pubmed: 30592986
J Hematother Stem Cell Res. 2001 Jun;10(3):419-25
pubmed: 11454317
Front Oncol. 2019 Aug 07;9:726
pubmed: 31448230
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
Mol Ther. 2017 Jan 4;25(1):285-295
pubmed: 28129122
Exp Hematol. 2015 Jun;43(6):462-8.e1
pubmed: 25795523
Blood. 2018 Aug 23;132(8):777-781
pubmed: 29914976
Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9236-41
pubmed: 10430926
Gene Ther. 2004 Jun;11(11):879-81
pubmed: 15057265
Lancet Oncol. 2019 Jan;20(1):31-42
pubmed: 30518502